URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Information about Adefovir
Adefovir dipivoxil is an acyclic nucleotide analogue of adenosine used either alone or in combination with other agents as therapy of chronic hepatitis B.
Liver safety of Adefovir
Adefovir does not appear to be a significant cause of drug induced liver injury, but initiation of therapy and sudden withdrawal of therapy can induce a transient exacerbation of the underlying hepatitis B.
Mechanism of action of Adefovir
Adefovir dipivoxil (bis-pom PMEA) is an acyclic nucleotide analog and prodrug of adefovir (a def' oh vir). The dipivoxil moiety is hydrolyzed after absorption, and adefovir is phosphorylated intracellularly to its active form, adefovir triphosphate, which competes with deoxyadenosine triphosphate for incorporation into the growing HBV DNA strand, causing inhibition of the viral DNA polymerase and chain termination. Adefovir is indicated for the treatment of chronic hepatitis B as a single agent and with lamivudine for lamivudine-resistant HBV infection.
FDA approval information for Adefovir
Adefovir was approved by the FDA in 2002 as therapy for hepatitis B. Adefovir is available generically and under the brand name Hepsera in 10 mg tablets. The recommended dose of adefovir is 10 mg orally once daily in adults and children age 12 years and older. The dose should be adjusted for renal impairment. Adefovir has minimal activity against human immunodeficiency virus (HIV) infection and is considered contraindicated in patients with HBV-HIV coinfection.
Recently, adefovir has been largely replaced by tenofovir which has a similar mechanism and spectrum of activity, but is approximately 30 times more potent against HBV.
Side effects of Adefovir
Side effects of adefovir include asthenia and renal injury which is marked by increases in serum creatinine levels, hypophosphatemia, hypouricemia and renal tubular acidosis.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza